Europe Antibody Drug Conjugates Market Size & Outlook

The antibody drug conjugates market in Europe is expected to reach a projected revenue of US$ 6,385.4 million by 2030. A compound annual growth rate of 19.4% is expected of Europe antibody drug conjugates market from 2022 to 2030.
Revenue, 2021 (US$M)
$1,299.4
Forecast, 2030 (US$M)
$6,385.4
CAGR, 2022 - 2030
19.4%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe antibody drug conjugates market, 2018-2030 (US$M)

Europe antibody drug conjugates market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe antibody drug conjugates market highlights

  • The Europe antibody drug conjugates market generated a revenue of USD 1,299.4 million in 2021.
  • The market is expected to grow at a CAGR of 19.4% from 2022 to 2030.
  • In terms of segment, breast cancer was the largest revenue generating application in 2021.
  • Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
  • Country-wise, Italy is expected to register the highest CAGR from 2022 to 2030.


Europe data book summary

Market revenue in 2021USD 1,299.4 million
Market revenue in 2030USD 6,385.4 million
Growth rate19.4% (CAGR from 2021 to 2030)
Largest segmentBreast cancer
Fastest growing segmentBlood Cancer
Historical data covered2018 - 2020
Base year for estimation2021
Forecast period covered2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBlood Cancer, Breast Cancer
Key market players worldwidePfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA


Other key industry trends

  • In terms of revenue, Europe region accounted for 22.4% of the global antibody drug conjugates market in 2021.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.

Breast cancer was the largest segment with a revenue share of 65.08% in 2021. Horizon Databook has segmented the Europe antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.


Major countries in the European ADC market are the UK, Spain, Italy, France, and Germany. Key factors driving this market include increasing incidence of cancer, improving accessibility of targeted drugs, favorable reimbursements, increasing government initiatives, and increasing R&D expenditure.

Furthermore, presence of strong pipeline products currently undergoing clinical trials in the region is expected to drive market growth over the forecast period. For instance, AstraZeneca and Sanofi are conducting multiple clinical trials for ADCs in the region.

In January 2021, Enhertu and datopotamab deruxtecan ADCs were revealed to show positive results in patients suffering from NSCLC, based on data presented by AstraZeneca & Daiichi Sankyo Company. The drugs were in Phase 2 and Phase 1 clinical trials, respectively.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antibody Drug Conjugates Market Companies

Name Profile # Employees HQ Website
ADC Therapeutics SA View profile 274 Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 https://www.adctherapeutics.com
GlaxoSmithKline Consumer Healthcare (GSK CH India) View profile 1001-5000 Gurgaon, Haryana, India, Asia https://india-consumer.gsk.com/
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Daiichi Sankyo Co Ltd View profile 17435 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 https://www.daiichisankyo.com
Takeda Pharmaceutical Co Ltd View profile 49095 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 https://www.takeda.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com

Europe antibody drug conjugates market size, by country, 2018-2030 (US$M)

Europe Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)

Europe antibody drug conjugates market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online